NCT04531670View on ClinicalTrials.gov

Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

February 28, 2023

Study Completion Date

February 28, 2023

Conditions
HIV Prevention ProgramOpioid-use Disorder
Interventions
BEHAVIORAL

iRaPID

Participants randomized to the iRaPID program will receive: a) same-day access to PrEP and OAT and educational counseling by the APN; b) safety-check phone calls/SMS; c) follow-up phone call/SMS; and d) clinical visit at Day 30

OTHER

Standard of Care

PWID participants randomized to the training as usual (TAU) will follow the existing clinical guidelines to receive PrEP, OAT, or both.

Trial Locations (1)

06520

Yale Clinical and Community Research, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Connecticut

OTHER

NCT04531670 - Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program | Biotech Hunter | Biotech Hunter